{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:17:29Z","timestamp":1792282649755,"version":"4.4.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR202111110012"],"award-info":[{"award-number":["ZR202111110012"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000853"],"award-info":[{"award-number":["82000853"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M721425"],"award-info":[{"award-number":["2022M721425"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jconrel.2025.113811","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:42:38Z","timestamp":1746272558000},"page":"113811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Delivery of Itgb1-siRNA by triptolide-modified and anti-Flt1 peptide-guided ionizable cationic LNPs for targeted therapy of corneal neovascularization"],"prefix":"10.1016","volume":"383","author":[{"given":"Yuwen","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianlu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huitang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0005","first-page":"794","article-title":"Targeting limbal epithelial stem cells: master conductors of corneal epithelial regeneration from the bench to multilevel theranostics","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113811_bb0010","first-page":"400","article-title":"MicroRNAs in the cornea: role and implications for treatment of corneal neovascularization","volume":"17","author":"Mukwaya","year":"2019","journal-title":"Ocul. Surf."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0015","first-page":"5","article-title":"Mechanisms of vessel pruning and regression","volume":"34","author":"Korn","year":"2015","journal-title":"Dev. Cell"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0020","first-page":"398","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel","year":"2018","journal-title":"Ocul. Surf."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113811_bb0025","first-page":"245","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0030","first-page":"926","article-title":"Deep corneal neovascularization after implantation with intrastromal corneal ring segments","volume":"140","author":"Al-Torbak","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113811_bb0035","article-title":"Up-to-date molecular medicine strategies for management of ocular surface neovascularization","volume":"201","author":"Yang","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0040","first-page":"415","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv. Ophthalmol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0045","first-page":"653","article-title":"Recent drug therapies for corneal neovascularization","volume":"90","author":"Liu","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113811_bb0050","first-page":"1159","article-title":"Anti-VEGF treatment in corneal diseases","volume":"21","author":"Giannaccare","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.jconrel.2025.113811_bb0055","first-page":"7605","article-title":"Enhancing the inhibition of corneal neovascularization efficacy by self-assembled into supramolecular hydrogel of anti-angiogenic peptide","volume":"19","author":"Pu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"10","key":"10.1016\/j.jconrel.2025.113811_bb0060","article-title":"Available therapeutic options for corneal neovascularization: a review","volume":"25","author":"Drzyzga","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113811_bb0065","first-page":"879","article-title":"Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs","volume":"50","author":"Alhamadani","year":"2022","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0070","first-page":"1483","article-title":"Effectiveness of Nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis","volume":"13","author":"Hagenacker","year":"2024","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0075","first-page":"128","volume":"18","author":"Lorenz","year":"2017","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113811_bb0080","first-page":"1683","article-title":"Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study","volume":"121","author":"Cursiefen","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2025.113811_bb0085","article-title":"Monitoring of nanodrug accumulation in murine breast cancer metastases","volume":"210","author":"Halim","year":"2024","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2025.113811_bb0090","first-page":"37","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154-155","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113811_bb0095","first-page":"2435","article-title":"Lipid nanoparticle Technology for Clinical Translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2025.113811_bb0100","first-page":"130","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113811_bb0105","first-page":"2175","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113811_bb0110","first-page":"614","article-title":"Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation","volume":"370","author":"Atsavapranee","year":"2024","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.jconrel.2025.113811_bb0115","first-page":"777","article-title":"Alnylam launches era of RNAi drugs","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"27","key":"10.1016\/j.jconrel.2025.113811_bb0120","first-page":"2603","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0125","first-page":"403","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113811_bb0130","unstructured":"Zhang, Y., et al., Principles of lipid nanoparticle design for mRNA delivery. BMEMat: p. e12116."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113811_bb0135","article-title":"Recent advancements in mRNA vaccines: from target selection to delivery systems","volume":"12","author":"Wu","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113811_bb0140","first-page":"1109","article-title":"Comparative study on the anti-inflammatory and immune suppressive effect of Wilforlide A","volume":"81","author":"Xue","year":"2010","journal-title":"Fitoterapia"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113811_bb0145","first-page":"922","article-title":"Effect of triptolide on T-cell receptor beta variable gene mRNA expression in rats with collagen-induced arthritis","volume":"295","author":"Wang","year":"2012","journal-title":"Anat. Rec. (Hoboken)"},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2025.113811_bb0150","first-page":"46","article-title":"Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells","volume":"52","author":"Zhu","year":"2010","journal-title":"Vasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113811_bb0155","first-page":"2250","article-title":"Modulation of Salmonella tumor-colonization and Intratumoral anti-angiogenesis by Triptolide and its mechanism","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113811_bb0160","first-page":"443","article-title":"Anti-tumor effects of triptolide on angiogenesis and cell apoptosis in osteosarcoma cells by inducing autophagy via repressing Wnt\/\u03b2-catenin signaling","volume":"496","author":"Li","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113811_bb0165","first-page":"5082","article-title":"Inhibition by triptolide of IL-1-induced collagen degradation by corneal fibroblasts","volume":"44","author":"Lu","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0170","first-page":"345","article-title":"The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle","volume":"51","author":"Mei","year":"2005","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0175","first-page":"194","article-title":"Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine","volume":"20","author":"Sun","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113811_bb0180","first-page":"2651","article-title":"Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis","volume":"11","author":"Bae","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"51","key":"10.1016\/j.jconrel.2025.113811_bb0185","article-title":"Manganese-coordinated mRNA vaccines with enhanced mRNA expression and immunogenicity induce robust immune responses against SARS-CoV-2 variants","volume":"8","author":"Fan","year":"2022","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113811_bb0190","article-title":"Antigen-specific mRNA lipid nanoparticle platforms for the prevention and treatment of allergy and autoimmune diseases","volume":"2","author":"Yim","year":"2024","journal-title":"BMEMat"},{"key":"10.1016\/j.jconrel.2025.113811_bb0195","first-page":"616","article-title":"Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery","volume":"341","author":"Swingle","year":"2022","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0200","first-page":"327","article-title":"Superior in vitro anticancer effect of biomimetic paclitaxel and triptolide co-delivery system in gastric cancer","volume":"35","author":"Wang","year":"2021","journal-title":"J. Biomed. Res."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113811_bb0205","first-page":"4713","article-title":"Activation of toll-like receptor 2 promotes mesenchymal stem\/stromal cell-mediated immunoregulation and angiostasis through AKR1C1","volume":"14","author":"Ko","year":"2024","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113811_bb0210","first-page":"1040","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0215","first-page":"162","article-title":"Mesenchymal stromal cells inhibit inflammatory Lymphangiogenesis in the cornea by suppressing macrophage in a TSG-6-dependent manner","volume":"26","author":"Song","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0220","article-title":"Targeted dexamethasone nano-prodrug for corneal neovascularization management","volume":"47","author":"Yin","year":"2024","journal-title":"Biom. J."},{"key":"10.1016\/j.jconrel.2025.113811_bb0225","first-page":"111","article-title":"Progress in research on the role of FGF in the formation and treatment of corneal neovascularization","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113811_bb0230","first-page":"14","article-title":"dsRNA induced IFN\u03b2-MMP13 Axis drives corneal wound healing","volume":"63","author":"Lan","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0235","first-page":"1246","article-title":"Integration of eQTL and a single-cell atlas in the human eye identifies causal genes for age-related macular degeneration","volume":"30","author":"Orozco","year":"2020","journal-title":"Cell Rep."},{"issue":"13","key":"10.1016\/j.jconrel.2025.113811_bb0240","first-page":"5","article-title":"Single-cell transcriptomics reveals cellular heterogeneity and complex cell-cell communication networks in the mouse cornea","volume":"64","author":"Wu","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113811_bb0245","first-page":"528","article-title":"A single-cell transcriptomic atlas of the human ciliary body","volume":"79","author":"Lou","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113811_bb0250","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0255","first-page":"9","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"7347","key":"10.1016\/j.jconrel.2025.113811_bb0260","first-page":"298","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113811_bb0265","first-page":"221","article-title":"Corneal neovascularization: molecular events and therapeutic options","volume":"3","author":"Shakiba","year":"2009","journal-title":"Recent Patents Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113811_bb0270","article-title":"A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis","volume":"76","author":"Guo","year":"2024","journal-title":"Drug Resist. Updat."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0275","first-page":"1272","article-title":"Anti-Flt1 peptide and cyanine-conjugated gold nanoparticles for the concurrent antiangiogenic and endothelial cell proton treatment","volume":"107","author":"Seo","year":"2019","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"10.1016\/j.jconrel.2025.113811_bb0280","first-page":"1","article-title":"Hyaluronic acid-endostatin2-alft1 (HA-ES2-AF) nanoparticle-like conjugate for the target treatment of diseases","volume":"288","author":"Sun","year":"2018","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113811_bb0285","first-page":"3115","article-title":"Anti-Flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy","volume":"32","author":"Oh","year":"2011","journal-title":"Biomaterials"},{"issue":"30","key":"10.1016\/j.jconrel.2025.113811_bb0290","first-page":"6026","article-title":"Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization","volume":"30","author":"Oh","year":"2009","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0295","first-page":"1149","article-title":"The role of inflammatory cytokines in neovascularization of chemical ocular injury","volume":"30","author":"Shahriary","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113811_bb0300","article-title":"Role of macrophage in ocular neovascularization","volume":"10","author":"Tu","year":"2024","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113811_bb0305","first-page":"C734","article-title":"Autocrine IL-1\u03b2 mediates the promotion of corneal neovascularization by senescent fibroblasts","volume":"315","author":"Dong","year":"2018","journal-title":"Am. J. Phys. Cell Physiol."},{"key":"10.1016\/j.jconrel.2025.113811_bb0310","article-title":"Triptolide decreases rheumatoid arthritis fibroblast-like synoviocyte proliferation, invasion, inflammation and presents a therapeutic effect in collagen-induced arthritis rats via inactivating lncRNA RP11-83J16.1 mediated URI1 and \u03b2-catenin signaling","volume":"99","author":"Piao","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2025.113811_bb0315","article-title":"Triptolide alleviates oxidized LDL-induced endothelial inflammation by attenuating the oxidative stress-mediated nuclear factor-kappa B pathway","volume":"97","author":"Zhang","year":"2022","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.jconrel.2025.113811_bb0320","first-page":"87","article-title":"Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice","volume":"319","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0325","article-title":"Homotypic cell membrane-camouflaged biomimetic PLGA nanoparticle loading triptolide for the treatment of hepatocellular carcinoma","volume":"31","author":"Li","year":"2024","journal-title":"Drug Deliv."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113811_bb0330","article-title":"Anterior segment optical coherence tomography angiography: a review of applications for the cornea and ocular surface","volume":"60","author":"Lee","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0335","first-page":"150","article-title":"Antitumor mechanisms and future clinical applications of the natural product triptolide","volume":"24","author":"Bao","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0340","first-page":"9","article-title":"Cerebral insulin, insulin signaling pathway, and brain angiogenesis","volume":"37","author":"Zeng","year":"2016","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0345","first-page":"37","article-title":"The secreted Ly6\/uPAR-related protein 1 (Slurp1) modulates corneal Angiogenic inflammation via NF-\u03baB signaling","volume":"65","author":"Swamynathan","year":"2024","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.113811_bb0350","article-title":"The protective effect of natural medicines in rheumatoid arthritis via inhibit angiogenesis","volume":"15","author":"Gao","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113811_bb0355","article-title":"B4GALNT1 promotes hepatocellular carcinoma stemness and progression via integrin \u03b12\u03b21-mediated FAK and AKT activation","volume":"5","author":"Tang","year":"2023","journal-title":"JHEP Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0360","first-page":"282","article-title":"THBS2+cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.113811_bb0365","article-title":"TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K\/AKT\/NF-\u03baB-signaling pathway to inhibit the polarization of M2 TAMs","volume":"11","author":"Le","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2025.113811_bb0370","article-title":"Corneal neovascularization","volume":"202","author":"Nicholas","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2025.113811_bb0375","first-page":"38","article-title":"Restoration of corneal epithelial barrier function: a possible target for corneal neovascularization","volume":"34","author":"Shen","year":"2024","journal-title":"Ocul. Surf."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0380","first-page":"331","article-title":"Advances in corneal graft rejection","volume":"32","author":"Yin","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113811_bb0385","first-page":"28","article-title":"Therapeutic approaches for corneal neovascularization","volume":"4","author":"Feizi","year":"2017","journal-title":"Eye Vis. (Lond.)"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0390","first-page":"505","article-title":"Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier","volume":"91","author":"Ambati","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113811_bb0395","first-page":"13","article-title":"Tissue-targeted and localized AAV5-DCN and AAV5-PEDF combination gene therapy abrogates corneal fibrosis and concurrent neovascularization in rabbit eyes in vivo","volume":"32","author":"Mohan","year":"2024","journal-title":"Ocul. Surf."},{"issue":"Pt B","key":"10.1016\/j.jconrel.2025.113811_bb0400","first-page":"32","article-title":"Thrombospondin-1 in vascular development, vascular function, and vascular disease","volume":"155","author":"Liu","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113811_bb0405","first-page":"533","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113811_bb0410","first-page":"1162","article-title":"Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma","volume":"42","author":"Li","year":"2022","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.jconrel.2025.113811_bb0415","first-page":"5860","article-title":"ATN-161 as an integrin \u03b15\u03b21 antagonist depresses ocular neovascularization by promoting new vascular endothelial cell apoptosis","volume":"24","author":"Sui","year":"2018","journal-title":"Med. Sci. Monit."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113811_bb0420","first-page":"407","article-title":"Nucleic acid-based drugs for patients with solid tumours","volume":"21","author":"Huayamares","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113811_bb0425","first-page":"673","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"34","key":"10.1016\/j.jconrel.2025.113811_bb0430","first-page":"8096","article-title":"Design, strategies, and therapeutics in nanoparticle-based siRNA delivery systems for breast cancer","volume":"11","author":"Yan","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113811_bb0435","first-page":"441","article-title":"RNA therapeutics on the rise","volume":"19","author":"Wang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0440","first-page":"49","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0445","first-page":"383","article-title":"Givosiran for the treatment of acute hepatic porphyria","volume":"15","author":"Ricci","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"20","key":"10.1016\/j.jconrel.2025.113811_bb0450","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"385","author":"Shah","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113811_bb0455","first-page":"709","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2025.113811_bb0460","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113811_bb0465","first-page":"763","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113811_bb0470","first-page":"1078","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113811_bb0475","first-page":"97","article-title":"Potential of solid lipid nanoparticles in brain targeting","volume":"127","author":"Kaur","year":"2008","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0480","first-page":"71","article-title":"Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids","volume":"19","author":"Oner","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113811_bb0485","first-page":"714","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113811_bb0490","first-page":"477","article-title":"Vascular heterogeneity and specialization in development and disease","volume":"18","author":"Potente","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113811_bb0495","article-title":"Effect of lipid nanoparticle Physico-chemical properties and composition on their interaction with the immune system","volume":"16","author":"Catenacci","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2025.113811_bb0500","article-title":"The role and mechanism of triptolide, a potential new DMARD, in the treatment of rheumatoid arthritis","volume":"104","author":"Wang","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113811_bb0505","first-page":"34","article-title":"Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K\/Akt signaling pathways","volume":"18","author":"Cheng","year":"2023","journal-title":"Chin. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925004316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:24:40Z","timestamp":1762259080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925004316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":101,"alternative-id":["S0168365925004316"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113811","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of Itgb1-siRNA by triptolide-modified and anti-Flt1 peptide-guided ionizable cationic LNPs for targeted therapy of corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113811"}}